Envista (NYSE:NVST) Price Target Raised to $23.00 at Evercore ISI

Envista (NYSE:NVST - Get Free Report) had its price target boosted by analysts at Evercore ISI from $19.00 to $23.00 in a report released on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Evercore ISI's price objective suggests a potential upside of 10.36% from the stock's previous close.

NVST has been the topic of several other research reports. UBS Group reduced their price target on shares of Envista from $21.00 to $18.00 and set a "neutral" rating on the stock in a research report on Monday, May 5th. Bank of America dropped their target price on shares of Envista from $26.00 to $23.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Piper Sandler decreased their price target on shares of Envista from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Baird R W raised shares of Envista from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 27th. Finally, Robert W. Baird upgraded shares of Envista from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $21.00 to $23.00 in a research report on Tuesday, May 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $20.23.

Envista Price Performance

NYSE NVST traded up $0.46 during trading hours on Wednesday, reaching $20.84. 866,235 shares of the company's stock were exchanged, compared to its average volume of 2,484,598. The firm has a fifty day moving average of $18.49 and a 200-day moving average of $18.49. Envista has a one year low of $14.22 and a one year high of $23.00. The stock has a market cap of $3.53 billion, a PE ratio of -3.19, a price-to-earnings-growth ratio of 1.28 and a beta of 1.00. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.43.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.04. The company had revenue of $616.90 million for the quarter, compared to analyst estimates of $608.17 million. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The business's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 earnings per share. On average, equities research analysts predict that Envista will post 1 earnings per share for the current fiscal year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank n.a. boosted its stake in Envista by 214.4% during the 1st quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock worth $36,000 after acquiring an additional 1,428 shares during the last quarter. Parallel Advisors LLC increased its stake in Envista by 100.1% in the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company's stock valued at $55,000 after purchasing an additional 1,397 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Envista in the fourth quarter worth $86,000. Palouse Capital Management Inc. raised its holdings in Envista by 14.4% in the first quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company's stock worth $163,000 after purchasing an additional 1,186 shares during the period. Finally, FourThought Financial Partners LLC bought a new position in shares of Envista during the first quarter worth $180,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.